E. Ohman J or Asset Management AB Decreases Stake in Natera, Inc. $NTRA

E. Ohman J or Asset Management AB lessened its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 8.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 27,395 shares of the medical research company’s stock after selling 2,400 shares during the period. E. Ohman J or Asset Management AB’s holdings in Natera were worth $5,479,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of NTRA. Robinhood Asset Management LLC acquired a new stake in shares of Natera in the 4th quarter worth approximately $12,981,000. Systrade AG acquired a new position in Natera during the fourth quarter worth $11,454,000. Quantbot Technologies LP acquired a new position in Natera during the third quarter worth $1,069,000. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in Natera by 5.7% during the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 159,166 shares of the medical research company’s stock worth $25,621,000 after purchasing an additional 8,630 shares during the last quarter. Finally, J. Safra Sarasin Holding AG purchased a new stake in Natera during the fourth quarter worth $2,825,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Royal Bank Of Canada started coverage on Natera in a report on Thursday, June 11th. They issued an “outperform” rating and a $275.00 target price on the stock. Morgan Stanley cut their price target on Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a research note on Tuesday, March 3rd. The Goldman Sachs Group initiated coverage on shares of Natera in a research report on Friday, June 5th. They issued a “neutral” rating and a $245.00 price objective on the stock. JPMorgan Chase & Co. increased their price objective on shares of Natera from $260.00 to $265.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Finally, BTIG Research dropped their target price on shares of Natera from $260.00 to $250.00 and set a “buy” rating for the company in a report on Monday, May 11th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $256.53.

Natera Stock Performance

Shares of NASDAQ NTRA opened at $231.41 on Friday. The firm has a market cap of $33.14 billion, a P/E ratio of -141.97 and a beta of 1.56. Natera, Inc. has a 1 year low of $131.81 and a 1 year high of $256.36. The firm’s 50 day moving average price is $208.20 and its 200 day moving average price is $215.52.

Insider Transactions at Natera

In other news, Director Rowan E. Chapman sold 2,964 shares of the business’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $216.78, for a total transaction of $642,535.92. Following the completion of the sale, the director directly owned 3,124 shares of the company’s stock, valued at $677,220.72. The trade was a 48.69% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Steven Leonard Chapman sold 41,124 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $221.03, for a total value of $9,089,637.72. Following the sale, the chief executive officer owned 108,743 shares of the company’s stock, valued at approximately $24,035,465.29. The trade was a 27.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 162,342 shares of company stock valued at $35,283,396 in the last quarter. Insiders own 5.05% of the company’s stock.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.